


# **INNOVATION IN MEDICAL TECHNOLOGIES**

## **IMPACT OF REGIONAL INNOVATION ECOSYSTEMS**

**MEDTECH4 EUROPE CONFERENCE, 17 NOVEMBER 2020**

# HOW EUROPE CAN BE MORE ATTRACTIVE FOR HEALTHCARE R&I

1. **BRINGING A DIVERSE SET OF STAKEHOLDERS TOGETHER, COMBINING WIDE SETS OF EXPERTISE;**
2. **BUILDING ON SPECIFIC EU ADVANTAGES OF GREATER SAFETY AND DATA PROTECTION STANDARDS, AS WELL AS UNIVERSAL HEALTHCARE;**
3. **INVESTING IN HEALTHCARE INNOVATION THROUGH PUBLIC PRIVATE PARTNERSHIPS (PPP) AND LARGE EU FUNDING INITIATIVES;**
4. **ESTABLISHING A MORE COORDINATED APPROACH FOR EU REGIONAL INNOVATION SYSTEMS**



# VALUE OF REGIONAL INNOVATION ECOSYSTEMS

- Innovation in medical technology requires the **cooperation of multiple partners** for funding, technologies development, scale up, validation and approval.
- Several innovation ecosystems mostly **supported by regional policies and local networks** (clusters, RTOs, large companies) facilitate the **interaction of partners** to speed up the R&I of innovative solutions.
- Common labs, affiliate programmes, pilot lines allowing a **common access to enabling technologies** would enable scale gains as tentatively explored with the electronic components and systems industry under the ECSEL Joint Undertaking.
- Co-investing in regional European ecosystems reinforces **trust in the EU medical technology industry locally**, including non-EU based companies.

# COORDINATION OF REGIONAL INNOVATION ECOSYSTEMS

- Due to the multicultural nature of the EU, there has been an emergence of **competing regional innovation ecosystems**.
- Beyond individual regional ecosystems, there is a critical lack of coordination among them. **A better interconnection and financial support of these innovation ecosystems throughout EU** would add value to their specificities, highlighting the “hotspots” in Europe.
- A more coordinated approach would **attract investment in ecosystems** bringing together a wide set of expertise, stakeholders, buyers and investors to support timely access of innovative solutions and overcome obstacles that can impede the journey from R&I to patients.



# THANK YOU

**PATRICK BOISSEAU**

**P.BOISSEAU@MEDTECHEUROPE.ORG**

[www.medtecheurope.org](http://www.medtecheurope.org)